

## **Sarepta Therapeutics Announces Appointment of Jean-Paul Kress, M.D. to the Company's Board of Directors**

CAMBRIDGE, Mass.--(BUSINESS WIRE)--September 30, 2015-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the appointment of Jean-Paul Kress, M.D., to the Company's Board of Directors.

Jean-Paul Kress, M.D., is the recently appointed Head of North America, Sanofi Genzyme Specialty Care Business Unit (Multiple Sclerosis, Oncology & Immunology). Prior to this appointment, Jean-Paul served as the President and CEO of Sanofi Pasteur MSD, the leading European vaccine company.

"We are very pleased to welcome Jean-Paul to our Board of Directors and gain the benefit of his commercial and organizational expertise as eteplirsen, our lead candidate for the treatment of patients with Duchenne muscular dystrophy, is pending review by the FDA," said Edward Kaye, M.D., Sarepta's interim chief executive officer and chief medical officer. "Jean-Paul is highly respected and his global experience and insights will be invaluable as we prepare for the potential commercialization of eteplirsen."

During his tenure with Sanofi Pasteur MSD, a joint venture between Sanofi Pasteur and Merck & Co (known as MSD outside the US and Canada), Jean-Paul embarked on a series of changes to reshape the organization to better meet the challenges of the rapidly changing vaccine industry and to drive the launches of a number of innovative new products. His ability to mobilize the organization to focus on the most critical priorities resulted in a turnaround of the business and provided a firm foundation for sustainable growth. A strong advocate for the socio-economic value of vaccination, Jean-Paul was actively involved in the development of health policy across the EU with a focus on disease prevention.

Prior to his work at Sanofi Pasteur MSD, Jean-Paul was Vice President and General Manager in France for Gilead, a major US-based biopharmaceutical company

specialized in therapeutics for life-threatening diseases such as HIV. He joined Gilead in California in 2006 as Vice President, US Sales and Marketing.

Jean-Paul Kress holds a MD Degree from Faculté Necker-Enfants Malades in Paris, France, and is an alumnus of the prestigious Ecole Normale Supérieure in Paris, France. He sits on the Board of Directors of CNE (the ENS Alumni association).

### **About Sarepta Therapeutics**

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of infectious diseases such as drug-resistant bacteria and other rare human diseases. For more information, please visit us at [www.sarepta.com](http://www.sarepta.com).

### **Forward-Looking Statements**

*This press release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “may,” “intends,” “prepares,” “looks,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating Mr. Kress’s membership on the Board, the potential benefits that Sarepta may gain from such membership and the value of his insights and global experience as Sarepta prepared for the potential commercialization of eteplirsen.*

*These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to capitalize on or benefit from Mr. Kress’ experience to commercialize eteplirsen or our other product candidates or technology; the results of our ongoing research and development efforts and clinical trials for eteplirsen and our other product candidates may not be positive or consistent with prior results or demonstrate a*

*safe treatment benefit there may be delays in Sarepta's projected regulatory and development timelines relating to the eteplirsen NDA and plans for commercializing eteplirsen and developing Sarepta's other product candidates for various reasons including possible limitations of Sarepta's financial and other resources; Sarepta may not be able to successfully complete its planned commercialization of eteplirsen or continue developing its product candidates as planned for a variety of reasons including due to regulatory, court or agency decisions, such as decisions by the USPTO with respect to patents that cover Sarepta's product candidates, scale-up of manufacturing may not be successful, and any or all of Sarepta's product candidates may fail in development or may not receive required regulatory approvals for commercialization (including potentially under an accelerated pathway); and those risks identified under the heading "Risk Factors" in Sarepta's 2014 Annual Report on Form 10-K or and most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.*

*Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.*

#### **Internet Posting of Information**

*We routinely post information that may be important to investors in the 'For Investors' section of our website at [www.sarepta.com](http://www.sarepta.com). We encourage investors and potential investors to consult our website regularly for important information about us.*

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Media and Investors:

Ian Estepan, 617-274-4052

iestepan@sarepta.com

or

W2O Group

Ryan Flinn, 415-946-1059

Mobile: 510-207-7616

rflinn@w2ogroup.com